Promising Drug Targets for Cancer: CTNS (G1497)

Target Name: CTNS

NCBI ID: G1497

CTNS

Promising Drug Targets for Cancer: CTNS

CTNS, or Colangial Transform growth factor beta, is a protein that is expressed in the smooth muscle of the intestine, which is responsible for the contractions that allow food to move through the digestive tract. In recent years, researchers have become interested in the potential role of CTNS in the development and progression of various diseases, including cancer.

One of the key reasons for the interest in CTNS is its ability to promote cell growth and division. This is because CTNS has been shown to play a role in the regulation of cell growth and cell division, which is important for the development and maintenance of tissues and organs.

In addition, CTNS has also been shown to play a role in the regulation of cell survival. This is because CTNS has been shown to help protect cells from the effects of chemotherapy and radiation, which can cause damage to cells and lead to the development of cancer.

Another promising aspect of CTNS is its ability to regulate the formation of blood vessels. This is important because the formation of blood vessels is a critical factor in the development of cancer, as blood vessels provide the necessary oxygen and nutrients to allow cancer cells to grow and divide.

Research has also shown that CTNS plays a role in the regulation of pain. This is because CTNS has been shown to help regulate the release of pain-causing chemicals in the body, which can help to explain why CTNS has been shown to be effective in reducing pain in animals.

Despite these promising findings, much more research is needed to fully understand the role of CTNS in the development and progression of cancer. In the future, researchers will be interested in studying the effects of drugs that target CTNS in order to develop new treatments for cancer.

In conclusion, CTNS is a protein that has been shown to play a role in the regulation of cell growth and division, cell survival, and the formation of blood vessels. In addition, CTNS has also been shown to play a role in the regulation of pain. These findings suggest that CTNS may be a promising drug target for the treatment of cancer. Further research is needed to fully understand its role and to develop new treatments.

Protein Name: Cystinosin, Lysosomal Cystine Transporter

Functions: Cystine/H(+) symporter that mediates export of cystine, the oxidized dimer of cysteine, from lysosomes (PubMed:11689434, PubMed:18337546, PubMed:22232659, PubMed:29467429, PubMed:33208952, PubMed:15128704). Plays an important role in melanin synthesis by catalyzing cystine export from melanosomes, possibly by inhibiting pheomelanin synthesis (PubMed:22649030). In addition to cystine export, also acts as a positive regulator of mTORC1 signaling in kidney proximal tubular cells, via interactions with components of the v-ATPase and Ragulator complexes (By similarity). Also involved in small GTPase-regulated vesicle trafficking and lysosomal localization of LAMP2A, independently of cystine transporter activity (By similarity)

The "CTNS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTNS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets